share_log

CVS Health | 8-K: Current report

CVS Health | 8-K: Current report

西维斯健康 | 8-K：重大事件
美股sec公告 ·  05/01 06:34
Moomoo AI 已提取核心信息
On May 1, 2024, CVS Health Corporation released its financial results for the first quarter of 2024, reporting a 3.7% increase in total revenues to $88.4 billion compared to the previous year. However, the company experienced a decrease in GAAP diluted EPS from $1.65 to $0.88 and Adjusted EPS from $2.20 to $1.31, primarily due to a decline in the Health Care Benefits segment's operating results, reflecting higher Medicare utilization. CVS Health revised its full-year 2024 guidance, lowering GAAP diluted EPS to at least $5.64 from $7.06, Adjusted EPS to at least $7.00 from $8.30, and cash flow from operations to at least $10.5 billion from $12.0 billion. The revision is based on the assumption that the elevated medical cost trends observed in the first quarter will persist throughout the year. CVS Health's CEO expressed confidence in the company's long-term earnings potential and strategy despite near-term challenges, particularly in the Medicare Advantage sector.
On May 1, 2024, CVS Health Corporation released its financial results for the first quarter of 2024, reporting a 3.7% increase in total revenues to $88.4 billion compared to the previous year. However, the company experienced a decrease in GAAP diluted EPS from $1.65 to $0.88 and Adjusted EPS from $2.20 to $1.31, primarily due to a decline in the Health Care Benefits segment's operating results, reflecting higher Medicare utilization. CVS Health revised its full-year 2024 guidance, lowering GAAP diluted EPS to at least $5.64 from $7.06, Adjusted EPS to at least $7.00 from $8.30, and cash flow from operations to at least $10.5 billion from $12.0 billion. The revision is based on the assumption that the elevated medical cost trends observed in the first quarter will persist throughout the year. CVS Health's CEO expressed confidence in the company's long-term earnings potential and strategy despite near-term challenges, particularly in the Medicare Advantage sector.
2024年5月1日，CVS Health Corporation发布了2024年第一季度的财务业绩，报告总收入与上年相比增长了3.7％，达到884亿美元。但是，该公司的GAAP摊薄后每股收益从1.65美元下降至0.88美元，调整后每股收益从2.20美元下降至1.31美元，这主要是由于医疗保健福利板块的经营业绩下降，反映了医疗保险利用率的提高。CVS Health修订了其2024年全年预期，将GAAP摊薄后每股收益从7.06美元下调至至少5.64美元，调整后每股收益从8.30美元下调至至少7.00美元，运营现金流从120亿美元降至至少105亿美元。该修订基于这样的假设，即第一季度观察到的医疗费用上涨趋势将持续到全年。尽管面临短期挑战，尤其是在Medicare Advantage领域，但CVS Health的首席执行官仍对公司的长期盈利潜力和战略充满信心。
2024年5月1日，CVS Health Corporation发布了2024年第一季度的财务业绩，报告总收入与上年相比增长了3.7％，达到884亿美元。但是，该公司的GAAP摊薄后每股收益从1.65美元下降至0.88美元，调整后每股收益从2.20美元下降至1.31美元，这主要是由于医疗保健福利板块的经营业绩下降，反映了医疗保险利用率的提高。CVS Health修订了其2024年全年预期，将GAAP摊薄后每股收益从7.06美元下调至至少5.64美元，调整后每股收益从8.30美元下调至至少7.00美元，运营现金流从120亿美元降至至少105亿美元。该修订基于这样的假设，即第一季度观察到的医疗费用上涨趋势将持续到全年。尽管面临短期挑战，尤其是在Medicare Advantage领域，但CVS Health的首席执行官仍对公司的长期盈利潜力和战略充满信心。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息